These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 12826158)
1. Effect of mycophenolate mofetil regimen on peripheral blood lymphocyte subsets in kidney transplant recipients. Bravo Soto JA; Esteban de la Rosa RJ; Luna del Castillo JD; Cerezo Morales S; García Olivares E; Osuna Ortega A; Asensio Peinado C Transplant Proc; 2003 Jun; 35(4):1355-9. PubMed ID: 12826158 [TBL] [Abstract][Full Text] [Related]
2. Influence of age, sex, and hepatitis C virus infection on peripheral blood lymphocyte subsets in stable kidney transplantation. Esteban de la Rosa RJ; Bravo Soto JA; Luna del Castillo JD; Morales SC; Olivares EG; Ortega AO; Peinado CA Transplant Proc; 2003 Dec; 35(8):2905-7. PubMed ID: 14697934 [TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate Mofetil Acute Renal Rejection Study Group Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415 [TBL] [Abstract][Full Text] [Related]
5. Effect of mycophenolate mofetil in heart transplantation. Mathieu P; Carrier M; White M; Pellerin M; Perrault L; Pelletier G; Robitaille D; Pelletier LC Can J Surg; 2000 Jun; 43(3):202-6. PubMed ID: 10851414 [TBL] [Abstract][Full Text] [Related]
6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
7. Conversion from azathioprine [correction of azathioprina] to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Ferraris JR; Tambutti ML; Redal MA; Bustos D; Ramirez JA; Prigoshin N Transplantation; 2000 Jul; 70(2):297-301. PubMed ID: 10933152 [TBL] [Abstract][Full Text] [Related]
8. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Pham PT; Pham PC Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327 [TBL] [Abstract][Full Text] [Related]
9. Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on the erythropoietic system of renal transplant recipients. Khosroshahi HT; Asghari A; Estakhr R; Baiaz B; Ardalan MR; Shoja MM Transplant Proc; 2006 Sep; 38(7):2077-9. PubMed ID: 16980004 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients. Böhler T; Canivet C; Galvani S; Therville N; Salvayre R; Negre-Salvayre A; Durand D; Thomsen M; Rostaing L; Kamar N Int Immunopharmacol; 2008 May; 8(5):769-73. PubMed ID: 18387521 [TBL] [Abstract][Full Text] [Related]
11. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine. Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Sollinger HW Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033 [TBL] [Abstract][Full Text] [Related]
13. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536 [TBL] [Abstract][Full Text] [Related]
14. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551 [TBL] [Abstract][Full Text] [Related]
15. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Kimball JA; Pescovitz MD; Book BK; Norman DJ Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860 [TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021 [TBL] [Abstract][Full Text] [Related]
18. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Meier-Kriesche HU; Friedman G; Jacobs M; Mulgaonkar S; Vaghela M; Kaplan B Transplantation; 1999 Nov; 68(10):1496-502. PubMed ID: 10589946 [TBL] [Abstract][Full Text] [Related]
19. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression. Lou HX; Vathsala A Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756 [TBL] [Abstract][Full Text] [Related]